Trenti Tommaso
Department of Laboratory Medicine & Pathology, University Hospital and Local Healthcare Unit of Modena, Italy.
EJIFCC. 2018 Dec 5;29(4):259-263. eCollection 2018 Dec.
The evidence-based recommendations for the evaluation of new tests to be used in practice are a key issue to improve diagnostic clinical pathway inducing effective care. Emerging precision or personalized medicine requires innovative and pioneering biomarker tests for molecularly targeted therapies, possibly fitted for the individual patient's condition. Beyond the traditional analytical specifications that should guarantee the proper clinical diagnostic performances in response to a specific clinical question, the outcomes of a new test should be clearly defined and evaluated. Analytical and diagnostic performances such as sensitivity, specificity, imprecision, positive and negative predictive values are traditionally established measures but the clinical impact and the healthcare outcomes, to which these accuracy measures are related, are complex to measure. The extent of the improvement of the patients' health due to a diagnostic test remains a "holy grail" notwithstanding it should be the ultimate goal.
评估实际应用中的新检测方法的循证建议是改善诊断临床路径以实现有效治疗的关键问题。新兴的精准医学或个性化医学需要用于分子靶向治疗的创新型和开拓性生物标志物检测,可能要适合个体患者的病情。除了应保证针对特定临床问题具有适当临床诊断性能的传统分析规范外,新检测方法的结果也应明确界定和评估。灵敏度、特异性、不精密度、阳性和阴性预测值等分析和诊断性能是传统的既定指标,但这些准确性指标所关联的临床影响和医疗保健结果却难以衡量。尽管诊断检测对患者健康的改善程度应是最终目标,但它仍是一个“圣杯”。